Biogen, Eisai's Alzheimer's Drug Succeeds in Mid-Stage Trial, Shares Soar Biogen, Eisai's Alzheimer's Drug Succeeds in Mid-Stage Trial, Shares Soar

Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news

Related Links:

Conditions:   Alzheimer Disease;   Mild Cognitive Impairment;   Subjective Cognitive Decline Intervention:   Other: No intervention Sponsor:   Barcelonabeta Brain Research Center, Pasqual Maragall Foundation Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
A laboratory screen found that a compound in the Yerba santa medicinal plant protects against several age-related triggers of death in mouse nerve cells.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news
Conditions:   Alzheimer Disease;   Mild Cognitive Impairment;   Subjective Cognitive Decline Intervention:   Other: No intervention Sponsor:   Barcelonabeta Brain Research Center, Pasqual Maragall Foundation Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 21 February 2019Source: NeuroImage: ClinicalAuthor(s): Chenfei Ye, Susumu Mori, Piu Chan, Ting MaAbstractA multivariate analytical strategy may pinpoint the structural connectivity patterns associated with Alzheimer's disease (AD) pathology in connectome-wide association studies. Diffusion magnetic resonance imaging data from 161 participants including subjects with healthy controls, AD, stable and converting mild cognitive impairment, were selected for group-wise comparisons. A multivariate distance matrix regression (MDMR) analysis was performed to detect abnormality in brain structural...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
In conclusion, memantine combined with citalopram can more effectively improve the cognitive function, and reduce behavioral and psychological symptoms in patients with moderate AD. Cardiac adverse effects of citalopram are not common when the dose is
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Publication date: Available online 21 February 2019Source: Advances in Child Development and BehaviorAuthor(s): Angela F. Lukowski, Helen M. Milojevich, Lauren EalesAbstractInfants and children with Down syndrome (DS) can look forward toward bright futures, as individuals with DS are living healthier, more productive lives than ever due to medical advances, opportunities for early and continued intervention, and inclusive education. Despite these advances, infants and children with DS experience challenges in specific domains of cognitive functioning relative to their typically developing (TD) peers. Over the long term, in...
Source: Advances in Child Development and Behavior - Category: Child Development Source Type: research
This paper reviews the pharmacological options which are currently available for treatment of Alzheimer disease, as well as potential new agents and approaches under investigation.U.S. Pharmacist
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Pharmacist Journal Article Source Type: news
In this study, we evaluated the serum half-lives and permeability into the brain and cerebrospinal fluid (CSF) of recombinant human (rh) proSP-C and Bri2 BRICHOS domains injected intravenously into WT mice. We found that rh proSP-C BRICHOS has a longer blood serum half-life compared with rh Bri2 BRICHOS and passed into the CSF but not into the brain parenchyma. As judged by Western blotting, immunohistochemistry, and ELISA, rh Bri2 BRICHOS passed into both the CSF and brain. Intracellular immunostaining for rh Bri2 BRICHOS was observed in the choroid plexus epithelium as well as in the cerebral cortex. Our results indicate...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Neurobiology Source Type: research
In this report, we combined the two most promising nutraceuticals with complementary anti-amyloidogenic properties: the plant-derived phenolics (−)-epigallocatechin-3-gallate (EGCG, an α-secretase activator) and ferulic acid (FA, a β-secretase modulator). We used transgenic mice expressing mutant human amyloid β-protein precursor and presenilin 1 (APP/PS1) to model cerebral amyloidosis. At 12 months of age, we orally administered EGCG and/or FA (30 mg/kg each) or vehicle once daily for 3 months. At 15 months, combined EGCG–FA treatment reversed cognitive impairment in most tests of learning and ...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Molecular Bases of Disease Source Type: research
More women than men are affected by Alzheimer's disease. New research suggests higher levels of tau deposits in women may explain this difference.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Source Type: news
More News: Alzheimer's | Health | Japan Health